Hillsdale Investment Management Inc. United Therapeutics Corp Transaction History

Hillsdale Investment Management Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$211.82 - $248.24 $10,591 - $12,412	50 Added 2.78%	1,850 $417,000
Q2 2023 Aug 11, 2023	BUY	$205.19 - $232.99 $10,259 - $11,649	50 Added 2.86%	1,800 $397,000
Q1 2023 May 10, 2023	BUY	$212.99 - $276.17 $362,083 - $469,489	1,700 Added 3400.0%	1,750 $391,000
Q2 2022 Aug 12, 2022	BUY	$174.81 - $241.14 $8,740 - $12,057	50 New	50 $12,000
Q3 2021 Oct 21, 2021	SELL	$179.86 - $214.88 $11,690 - $13,967	-65 Closed	0 $0
Q2 2021 Jul 29, 2021	SELL	$170.47 - $211.93 $613,692 - $762,948	-3,600 Reduced 98.23%	65 $12,000
Q1 2021 Apr 22, 2021	SELL	$153.94 - $174.85 $69,273 - $78,682	-450 Reduced 10.94%	3,665 $613,000
Q4 2020 Feb 09, 2021	BUY	$101.87 - $151.79 $5,093 - $7,589	50 Added 1.23%	4,115 $625,000
Q3 2020 Nov 13, 2020	BUY	$99.9 - $121.13 $9,990 - $12,113	100 Added 2.52%	4,065 $411,000
Q2 2020 Aug 11, 2020	BUY	$92.74 - $125.82 $367,714 - $498,876	3,965 New	3,965 $480,000

673

42.2M

194K

295K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.6B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Hillsdale Investment Management Inc., based on Form 13F filings with the SEC.

Stay updated on Hillsdale Investment Management Inc. with notifications on news.